Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 11, 2024Scientific ReportsOpen Access

Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD

View Full Paper
Ask AI
Bookmark
Share

Authors

JIJin ImaiTokai UniversitySTShinji TakashimizuTokai UniversityNSNana SuzukiAsahikawa Medical University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Imai et al. (2024) studied this question.

synapsesocial.com/papers/68e65431b6db6435875e34e3https://doi.org/10.1038/s41598-024-64301-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes2015 · 11,061 citations
  2. 2Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases2017 · 1,220 citations
  3. 3Metabolic dysfunction–associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study2021 · 92 citations
  4. 4MAFLD: How is it different from NAFLD?2022 · 427 citations
  5. 5Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B2021 · 115 citations